<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Infect. Microbiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cellular and Infection Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Infect. Microbiol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2235-2988</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fcimb.2026.1819326</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Synergistic antibacterial effect of CATH-2 and D-amino acids against mastitis causing gram-positive bacteria</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Veldhuizen</surname><given-names>Edwin J.A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/334362/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>van der Velden</surname><given-names>Sasja T.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Alons</surname><given-names>David</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Benedictus</surname><given-names>Lindert</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/572325/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>van der Drift</surname><given-names>Indy</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Ludwig</surname><given-names>Irene S.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/536322/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Schreutelkamp</surname><given-names>Danique E.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>W&#xf6;sten</surname><given-names>Marc M.S.M.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/43142/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department Biomolecular Health Sciences, Utrecht University</institution>, <city>Utrecht</city>,&#xa0;<country country="nl">Netherlands</country></aff>
<aff id="aff2"><label>2</label><institution>Department Population Health Sciences, Utrecht University</institution>, <city>Utrecht</city>,&#xa0;<country country="nl">Netherlands</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Marc M.S.M. W&#xf6;sten, <email xlink:href="mailto:m.wosten@uu.nl">m.wosten@uu.nl</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-05-29">
<day>29</day>
<month>05</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>16</volume>
<elocation-id>1819326</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>02</month>
<year>2026</year>
</date>
<date date-type="rev-recd">
<day>03</day>
<month>04</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>04</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Veldhuizen, van der Velden, Alons, Benedictus, van der Drift, Ludwig, Schreutelkamp and W&#xf6;sten.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Veldhuizen, van der Velden, Alons, Benedictus, van der Drift, Ludwig, Schreutelkamp and W&#xf6;sten</copyright-holder>
<license>
<ali:license_ref start_date="2026-05-29">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>To effectively treat bacterial diseases caused by antibiotic-resistant strains, new antimicrobial agents are needed to overcome this resistance. This study explored whether the combination of the antimicrobial peptide CATH-2 with positively charged D-amino acids can be used as a potential alternative to antibiotics for treatment of mastitis in cows.</p>
</sec>
<sec>
<title>Methods</title>
<p>Antibacterial assays and bacterial growth kinetics were assessed in the presence of CATH-2 combined with either D-arginine or D-lysine. Synergistic interactions between the two components were evaluated using checkerboard assays. Cytotoxicity of the tested compounds was determined through WST, LDH release, and trypan blue exclusion assays on multiple mammalian cell lines, including bovine udder epithelial cells.</p>
</sec>
<sec>
<title>Results</title>
<p>The combination of CATH-2 and D-arginine showed strong synergistic antibacterial activity against Gram-positive bacteria, including all tested multidrug-resistant clinical <italic>Staphylococcus aureus</italic> isolates, in both LB medium (FIC&#xa0;=&#xa0;0.37) and fresh raw milk (FIC &lt; 0.12). No detectable cytotoxic effects on bovine udder epithelial cells or other epithelial cell lines were observed at concentrations that were effective against bacterial growth.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>This novel combination of an antimicrobial peptide with a positively charged D-amino acid offers promising potential for treating bacterial infections, particularly those caused by antibiotic-resistant strains.</p>
</sec>
</abstract>
<kwd-group>
<kwd>alternative to antibiotic</kwd>
<kwd>antimicrobial peptide</kwd>
<kwd>cathelicidins</kwd>
<kwd>d-amino acids</kwd>
<kwd>host defense peptides</kwd>
<kwd>infection</kwd>
<kwd>mastitis</kwd>
<kwd><italic>Staphylococcus aureus</italic></kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="9"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="33"/>
<page-count count="14"/>
<word-count count="7144"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Antibiotic Resistance and New Antimicrobial drugs</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>The overuse and misuse of antibiotics in human and animal health and agriculture have contributed to the rise of antibiotic-resistant bacterial strains, creating a global issue that requires urgent action and innovative solutions (<xref ref-type="bibr" rid="B6">Ho et&#xa0;al., 2025</xref>). This crisis makes infections harder to treat, puts modern medicine at risk, and has led to millions of deaths globally. Preferably, alternatives to conventional antibiotics should act through mechanisms distinct from those of classic antibiotics, thereby avoiding cross-resistance, and should not themselves promote the development of bacterial resistance.</p>
<p>A potential alternative for the use of antibiotics is the use of antimicrobial peptides (AMPs). These small cationic proteins have broad spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria (<xref ref-type="bibr" rid="B1">Ageitos et&#xa0;al., 2017</xref>). Most AMPs act by binding to the negatively charged bacterial membrane leading to permeabilization of this membrane and subsequent leakage of the cytosolic content, eventually killing the bacterium (<xref ref-type="bibr" rid="B17">Mookherjee et&#xa0;al., 2020</xref>). The AMP CATH-2, is a 26 amino-acid AMP from chickens which has shown high antibacterial activity against a&#xa0;number of bacteria (<xref ref-type="bibr" rid="B29">van Dijk et&#xa0;al., 2009</xref>). Importantly, it was&#xa0;described that long term exposure of bacterial strains to low&#xa0;levels of&#xa0;CATH-2 did not lead to development of bacterial resistance, unlike common antibiotics (<xref ref-type="bibr" rid="B31">Veldhuizen et&#xa0;al., 2013</xref>). There are however some concerns regarding the therapeutic use of&#xa0;AMPs, under physiological conditions they often lose their activity as they&#xa0;are susceptible to proteases (<xref ref-type="bibr" rid="B22">Rima et&#xa0;al., 2021</xref>). Incorporation of D-amino acids into AMPs has demonstrated to&#xa0;improve their pharmacokinetic properties and therapeutic effectiveness (<xref ref-type="bibr" rid="B14">Li et&#xa0;al., 2016</xref>).</p>
<p>D-amino acids, the enantiomeric counterparts of L-amino acids, might be another potential alternative for antibiotics. They have been long believed to play only a minor role in bacteria as part of the peptidoglycan layer of the bacterial cell wall. Nowadays we know that they are also found in animals and humans where they play a major role in several physiological processes and functions, such as signaling molecules in neurotransmission (<xref ref-type="bibr" rid="B3">Bastings et&#xa0;al., 2019</xref>) and hormone secretion (<xref ref-type="bibr" rid="B8">Homma, 2007</xref>). In 2009, it was shown that several bacteria secrete millimolar concentrations of D-amino acids into their environment (<xref ref-type="bibr" rid="B12">Lam et&#xa0;al., 2009</xref>). These secreted D-amino acids can have regulatory roles, including inhibition of competing bacteria in polymicrobial communities, such as biolfilms (<xref ref-type="bibr" rid="B13">Leiman et&#xa0;al., 2013</xref>). For example, <italic>Vibrio cholerae</italic> uses D-arginine as a toxic extracellular effector influencing the growth and morphogenesis of competing microbes (<xref ref-type="bibr" rid="B2">Alvarez et&#xa0;al., 2018</xref>).</p>
<p>Mastitis in cows is an inflammatory condition of the udder tissue, commonly caused by bacterial infection, and is one of the most significant diseases in dairy cows, compromising welfare and leading economic losses impact on dairy farms (<xref ref-type="bibr" rid="B5">Goulart and Mellata, 2022</xref>; <xref ref-type="bibr" rid="B21">Rainard et&#xa0;al., 2018</xref>). In the Netherlands the financial losses for the dairy industry are on average &#x20ac;240/lactating cow per year (<xref ref-type="bibr" rid="B28">Urakawa et&#xa0;al., 2022</xref>; <xref ref-type="bibr" rid="B30">van Soest et&#xa0;al., 2016</xref>). The disease can be classified into clinical and subclinical forms, with clinical mastitis presenting visible signs such as swelling, redness, and abnormal milk, while subclinical mastitis often remains undetected but can lead to substantial losses in milk yield and quality. The main pathogens responsible for bovine mastitis are the Gram-positive bacteria <italic>Staphylococcus aureus, Streptococcus uberis</italic> and <italic>Streptococccus agalactiae</italic> and the Gram-negative bacterium <italic>Escherichia coli</italic> (<xref ref-type="bibr" rid="B5">Goulart and Mellata, 2022</xref>). Antibiotic treatment is the current preferred treatment option, but antibiotic resistance is a growing concern in the treatment of mastitis in dairy cows (<xref ref-type="bibr" rid="B9">Inamullah et&#xa0;al., 2025</xref>), complicating management strategies and threatening animal welfare.</p>
<p>This study aimed to investigate whether the antimicrobial activity of CATH-2 could be enhanced by specific D-amino acids, offering a potential novel treatment for mastitis caused by antibiotic-resistant <italic>S. aureus</italic>, <italic>E. coli, S. uberis and S. agalactiae</italic> bacteria.</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2_1">
<title>Bacterial strains tissue culture cells and media</title>
<p><italic>S. aureus</italic> WKZ2 (<xref ref-type="bibr" rid="B10">Jansen et&#xa0;al., 2006</xref>) and USA300 (<xref ref-type="bibr" rid="B4">Diep et&#xa0;al., 2006</xref>) are multi-resistant strains, <italic>S. aureus</italic> Saujes and JHs139 were isolated from a cow with subclinical mastitis, <italic>S. aureus</italic> JHs58 was isolated from a cow with clinical mastitis (<xref ref-type="bibr" rid="B7">Hoekstra et&#xa0;al., 2018</xref>), while <italic>S. aureus</italic> ATCC25923 is a clinical isolate from a human wound infection. <italic>E. coli</italic> strain 1120&#x2013;2 was isolated from a clinical mastitis case (isolated at our Population Health Sciences department). <italic>S. uberis</italic> 233 h4c1 and <italic>S. agalactiae</italic> are two clinal mastitis isolates (<xref ref-type="bibr" rid="B27">Swanson et&#xa0;al., 2009</xref>). <italic>S. aureus</italic> and <italic>E. coli</italic> were cultured on Luria Broth Agar plates (Thermo Scientific Oxoid, Basingstoke, UK), while <italic>S. uberis</italic> and <italic>S. agalactiae</italic> were cultured on Sheep blood agar plates. A single colony was picked from all strains for o/n growth in Luria Broth (LB, BioTRADING Benelux B.V., Mijdrecht, The Netherlands). HeLa cells (<xref ref-type="bibr" rid="B23">Rodriguez et&#xa0;al., 1999</xref>) and Caco-2 cells (ATCC-HTB-37) were grown in 25 cm<sup>2</sup> flasks in Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM) containing 10% fetal calf serum (FCS) at 37&#x2da;C and 10% CO<sub>2</sub>. The <italic>parenchyme s&#xe9;cr&#xe9;toire</italic> (PS) cell line (<xref ref-type="bibr" rid="B24">Roussel et&#xa0;al., 2015</xref>), a spontaneously immortalized cell line originating from cultured primary bovine mammary epithelial cells (bMECs), was cultured in T25 flasks containing advanced DMEM Media (RSM, Gibco, Thermo Fisher Scientific, MA, USA) including 10 ng/ml Insulin like growth factor (IGF-1), 5 ng/ml Fibroblast growth factor (FGF), 5 ng/ml Epidermal growth factor (EGF), 0.01% Hydrocortisone, 2% Hepes and 1% Glutamax. The cell line was cultured at 37&#xa0;&#xb0;C with a humidified atmosphere of 10% CO<sub>2</sub>.</p>
</sec>
<sec id="s2_2">
<title>Peptide synthesis</title>
<p>Chicken cathelicidin 2 (CATH-2), RFGRFLRKIRRFRPKVTITIQGSARF, was synthesized by China Peptides (Shanghai, China) using Fmoc-chemistry. The peptide was purified by reverse phase high-performance liquid chromatography to a purity of &gt;95%.</p>
</sec>
<sec id="s2_3">
<title>Chemicals</title>
<p>D-amino acids used in this study were purchased from Sigma-Aldrich Inc (Saint Louis, Missouri, US).</p>
</sec>
<sec id="s2_4">
<title>Growth curves</title>
<p>Growth curves of <italic>S. aureus</italic>, <italic>E. coli, S. uberis and S. agalactiae</italic> were recorded on a BioTek Synergy HTX Multimode Reader. In a standard assay 200 &#xb5;l of bacteria with a final density of 1x10<sup>6</sup> CFU/ml was added to a flatbottom 96 wells plate in the presence (or&#xa0;absence) of varying concentrations of CATH-2 and D-amino acids. The OD<sub>600</sub> was measured every 10&#xa0;min for 24&#xa0;h at 37&#xa0;&#xb0;C under continuous shaking.</p>
</sec>
<sec id="s2_5">
<title>Colony count assays under aerobic conditions</title>
<p><italic>S. aureus</italic> and <italic>E. coli</italic> cultures were grown from a fresh overnight culture to logarithmic phase in LB under constant shaking of 160 RPM at 37&#xa0;&#xb0;C. From logarithmic phase the bacteria were diluted to a density of 1x10<sup>6</sup> CFU/ml. To 25 &#xb5;l bacterial solution 25 &#xb5;l LB was added containing CATH-2 (0-40 &#xb5;M) and D-Arginine (0&#x2013;20 mM) in a polypropylene round bottom 96 wells plate. After 3&#xa0;h incubation at 37&#xa0;&#xb0;C, serial 10-fold dilutions were prepared, which were plated on Tryptone Soy Agar (TSA) plates. After o/n incubation at 37&#xa0;&#xb0;C, viable bacteria were counted.</p>
</sec>
<sec id="s2_6">
<title>Colony count assays under anaerobic conditions</title>
<p>Overnight cultures of <italic>S. aureus</italic> and <italic>E. coli</italic> were grown anaerobically under constant shaking of 160 RPM at 37&#xa0;&#xb0;C. Bacteria were diluted to a concentration of 1x10<sup>6</sup> CFU/ml in LB and incubated with 20 mM D-Arg with or without 5 &#xb5;M CATH-2 under anaerobic conditions. At various times during the 3&#xa0;h incubation, samples were taken, serially diluted in 10-fold increments and plated on TSA plates. After o/n incubation at 37&#xa0;&#xb0;C, viable bacteria were counted.</p>
</sec>
<sec id="s2_7">
<title>Determination of synergy between CATH-2 and D-Arg</title>
<p>Checkerboard dilution assays were performed both in LB and raw milk to determine possible synergy between CATH-2 and D-Arg. For the assays in LB, 1x10<sup>6</sup> CFU/ml <italic>S. aureus</italic>, <italic>S. uberis</italic> or <italic>S. agalactiae</italic> were treated in 96 wells plates with all combinations (using twofold dilutions) of CATH-2 (0-80 &#xb5;M) and D-Arg (0&#x2013;160 mM). Visual determination of growth was performed after 24&#xa0;h incubation at 37&#xa0;&#xb0;C. In raw milk a similar set-up was used but growth was determined by plating out the incubation mixtures on TSA, because visual determination of growth is impossible due to the turbidity of the milk. Separate MBC determinations for D-Arg only and CATH-2 only in milk were performed because they were outside of the used concentrations in the checkerboard assays. Synergy was determined by calculating the fractional inhibitory concentration index (FICI) = MIC of drug A in combination/MIC of drug A alone + MIC of drug B in combination/MIC of drug B alone. In milk the MBC of CATH-2 was 320 &#xb5;M, while D-Arg did not obtain an MBC at 320 mM, but 320 mM was used for FICI calculations. The calculated FICI was interpreted as synergistic for FICI &lt;0.5, additive: 0.5&lt; FICI&lt;1; indifferent (1&lt; FICI &lt;4.0), or antagonistic FICI&gt; 4.</p>
</sec>
<sec id="s2_8">
<title>Toxicity: WST-1 assay</title>
<p>To study the effect of CATH-2 and D-Arg on cell viability, Hela cells and Caco-2 cells were seeded at a density of 2x10<sup>4</sup> cells per well in 96 well plates. These cells were subjected to various concentrations of CATH-2 and D-Arg in growth medium for 4&#xa0;h. Following the incubation period, the culture medium was substituted with 100 &#x3bc;L of new medium solution containing 10% water-soluble tetrazolium 1 (WST-1) (Roche, Basel, Switzerland). Subsequent colorimetric analysis was conducted after a 10&#x2212;15 min incubation period at 450 nm using a FLUOstar Omega microplate reader (BMG Labtech GmbH, Ortenberg, Germany). Cell viability was then quantified as a percentage, with 100% indicating the viability of untreated cells.</p>
</sec>
<sec id="s2_9">
<title>Toxicity: LDH leakage assay</title>
<p>Toxicity of CATH-2 and D-Arg toward Hela and Caco-2 cells was determined by the LDH release assay, as described previously. In short, cells were incubated with combinations of CATH-2 and D-Arg for 4&#xa0;h and cytotoxicity was evaluated by measuring the proportion of LDH released into the supernatant. Cytotoxicity was expressed relative to the maximum LDH release observed in cells lysed with Triton X-100 detergent. This assessment was performed using the Cyto Tox 96 nonradioactive cytotoxicity kit (Promega), following the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2_10">
<title>Toxicity assay with PS (bMEC) cells</title>
<p>The PS cells were seeded at a density of 2x10<sup>4</sup> cells per well in a flat-bottom polystyrene 96-well plate and o/n incubated at 37&#xa0;&#xb0;C and 10% CO<sub>2</sub>, which allowed attachment and proliferation of the cells, thereby forming a monolayer of cells. The cells were subjected to various concentrations of CATH-2 (0-40 &#xb5;M) and D-Arg (0&#x2013;40 mM) dissolved in day-fresh raw milk for a duration of 1&#xa0;h and 4&#xa0;h. All solutions were prepared such as to contain 85% raw milk and 15% water. As a positive control, cells were exposed to methanol for a duration of 1&#xa0;min. After incubation, the cells were washed two times with PBS, followed by a 5&#xa0;min incubation with 1:1 trypan blue. The cells were washed an additional two times with PBS. To ensure accurate quantification, four non-overlapping images were acquired per well and the stained and unstained cells were counted.</p>
</sec>
<sec id="s2_11">
<title>Antibacterial activity of CATH-2 and D-Arg, D-Lys or D-ser in milk</title>
<p>In order to determine the antibacterial activity of CATH-2 and D-Arg in a relevant medium, colony count assays were performed in raw milk (Farm De Tolakker of the Veterinary Faculty, Utrecht). <italic>S. aureus</italic> cultures were grown to logarithmic phase as described above. Subsequently, fresh, bulk tank milk, 4<sup>0</sup>C was spiked with 1x10<sup>6</sup> CFU/ml <italic>S. aureus</italic> and subsequently treated with CATH-2 and D-Arg, D-Lys or D-Ser from stock solutions in milliQ, (resulting in a final percentage of 85% milk, 0.2% LB and 14.8% water) and incubated at 37&#xa0;&#xb0;C. At varying time points small aliquots were taken from the incubation mixture, serially diluted and plated on TSA plates. These were incubated for 24&#xa0;h at 37&#xa0;&#xb0;C and viable bacteria were counted.</p>
</sec>
<sec id="s2_12">
<title>Isothermal titration calorimetry</title>
<p>The experiments were performed on a NanoITC (TA Instruments, New Castle, USA). All components (CATH-2, <italic>Pseudomonas aeruginosa</italic> LPS, and D-Arg) were diluted to the indicated concentrations in 75% (v:v) phosphate-buffered saline (PBS). The 164 &#xb5;l chamber was filled with 100 &#xb5;M CATH-2 and the syringe with 1 mM D-Arg. Titrations were incremental with 2 &#xb5;l injections at 300 s intervals. Experiments were performed at 37&#xa0;&#xb0;C. Control experiments were performed titrating 1 mM D-Arg into a 75% PBS solution in the chamber (negative control) and titrating 200 &#xb5;M CATH-2 into 10 &#xb5;M LPS (positive binding control).</p>
</sec>
<sec id="s2_13">
<title>Statistical analysis</title>
<p>Statistical analysis was performed using Graphpad Prism 10 (GraphPad, San Diego, CA). Data is expressed as mean with SEM. Results of growth curve and survival test assays were analyzed by measuring the area under the curve, followed by one-way Anova using Dunnett&#x2019;s multiple comparisons test. Toxicity data were analyzed using a one-way Anova. P-value of &lt;0.05 was considered statistically significant. (*P&lt;0.05, **P&lt;0.01, ***P&lt;0.001, ****P&lt;0.0001).</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Antibacterial activity of D-Amino acids</title>
<p>The antimicrobial peptide CATH-2 is known to possess antibacterial activity, however the activity of antimicrobial peptides are often strongly dependent on the presence of proteases and divalent cations (<xref ref-type="bibr" rid="B17">Mookherjee et&#xa0;al., 2020</xref>). As certain D-Amino Acids (D-AAs) are known to enhance the effectiveness of antibiotics (<xref ref-type="bibr" rid="B33">Yang et&#xa0;al., 2024</xref>), we sought to explore whether D-AAs could also boost the efficacy of CATH-2. Therefore, we tested whether all soluble D-AAs in combination with or without sublethal concentrations of CATH-2 possess antimicrobial properties against multi-antibiotic resistant isolate <italic>S. aureus</italic> strain WKZ2. First the final optical density of <italic>S. aureus</italic> cultures containing sublethal 2 &#xb5;M CATH-2 with or without 20 mM D-AA was measured. No bacterial growth defect was observed when only 2 &#xb5;M CATH-2 was added (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1A</bold></xref>). When D-amino acids were added on their own, only D-Nor, D-Thr and D-Val slightly reduced the final optical density of the culture compared to LB alone. However, when CATH-2 was combined with either D-Lys or D-Arg a strong reduction of the optical density, <italic>i.e.</italic> bacterial growth inhibition was observed, indicating that CATH-2 together with these two D-amino acids are potentially synergistic antibacterial combinations.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Antibacterial effect of D-Arginine and CATH-2. <bold>(A)</bold> Growth curves of S. aureus WKZ2 were generated in the presence or absence of 2 &#xb5;M CATH-2 and 20 mM D-AA in LB at 37&#xa0;&#xb0;C. The mean final OD600 values after 12 hours from 3 replicates of 3 independent experiments are schematically shown in a heatmap. Growth curves of S. aureus WKZ were generated with different concentrations of D-Arg as indicated with <bold>(B)</bold> 0 &#xb5;M CATH-2; <bold>(C)</bold> 1.25 &#xb5;M CATH-2; <bold>(D)</bold> 2.5 &#xb5;M CATH-2 and <bold>(E)</bold> 5 &#xb5;M CATH-2 at 37&#xa0;&#xb0;C and growth was determined by measuring OD<sub>600</sub> every 10&#xa0;min. Data are represented as mean &#xb1; SEM of three independent experiments. P-value, *P &lt; 0.05, **P &lt; 0.01, ***P &lt; 0.001, ****P &lt; 0.0001. <bold>(F)</bold> Bacterial viability was determined after S. aureus WKZ2 was incubated for 3&#xa0;h with different concentrations of D-Arg and CATH-2. Shown are the average + SEM of 3 independent experiments. P-value, *P &lt; 0.05, **P &lt; 0.01.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g001.tif">
<alt-text content-type="machine-generated">Panel A displays a heatmap comparing effects of D-amino acids and CATH-2 on bacterial growth, with red indicating growth inhibition and green indicating no inhibition. Panels B to E growth curves (OD600 over 24 hours) with different concentrations of D-arginine and CATH-2, indicating that combinations of CATH-2 and D-arginine significantly inhibit bacterial growth compared to controls, with statistical significance denoted by asterisks. Panel F presents a line graph showing log colony forming units per milliliter as a function of CATH-2 concentration, demonstrating reduced bacterial survival with increasing concentrations of D-arginine and CATH-2.</alt-text>
</graphic></fig>
<p>Next, growth curves were generated of <italic>S. aureus</italic> JHs58 (a clinical mastitis isolate) in the presence of 0&#x2013;40 mM D-Arg, D-Lys or D-Ser (as negative control). At concentrations of 20 mM and 40 mM D-Arg and to a lower extend with D-Lys, growth of <italic>S. aureus</italic> was inhibited as seen by the extended lag time (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;S1</bold></xref>). However, this inhibitory effect was absent at lower concentrations of these D-amino acids. D-Ser showed no impact on <italic>S. aureus</italic> growth at any concentration tested.</p>
</sec>
<sec id="s3_2">
<title>Antibacterial activity of CATH-2 in combination with D-Arg or D-Lys</title>
<p>To address how CATH-2 combined with D-Arg or D-Lys influence the growth of <italic>S. aureus</italic> we generated growth curves using varying concentrations CATH-2 (0-5 &#xb5;M) and D-Arg or D-Lys (0 to 20 mM) (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1B&#x2013;E</bold></xref>). We observed that by increasing the amount of D-Arg or D-Lys in the presence of CATH-2, not only the lag phase extended, but also the slope and to a lower extend the final optical density was reduced. This suggest that it takes longer before the bacteria have been adapted to the culture medium and that uptake of nutrients is slower in the presence of both components. No growth was observed with 2.5 &#xb5;M CATH-2 with 20 mM D-Arg or 5 &#xb5;M CATH-2 with 5-, 10- or 20 mM D-Arg (<xref ref-type="fig" rid="f1"><bold>Figures&#xa0;1D, E</bold></xref>). Similar results were obtained for CATH-2 and D-Lys (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;S2</bold></xref>).</p>
<p>To explore the effects of combined treatment with CATH-2 and D-Arg on the survival of <italic>S. aureus</italic>, colony count assays were performed using different concentrations of D-Arg (0&#x2013;20 mM) and CATH-2 (0-40 &#xb5;M). As depicted in <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1F</bold></xref>, CATH-2 alone was relatively weakly active against <italic>S. aureus</italic>. However, addition of 5 mM or higher concentrations of D-Arg had a strong concentration-dependent positive effect on the antibacterial activity of CATH-2 leading to MBC values of 10 &#xb5;M and lower.</p>
</sec>
<sec id="s3_3">
<title>All <italic>S. aureus</italic> strains are sensitive to the CATH-2/D-Arg combination</title>
<p>To rule out strain-specificity of the observed antibacterial effect of the CATH-2/D- Arg combinations, we subsequently tested six different <italic>S. aureus</italic> strains. The strains included two multi-resistant <italic>S. aureus</italic> strains (WKZ2 and USA300), two strains isolated from a cow with subclinical mastitis (JHs139 and SauJes), one from a cow with clinical mastitis (JHs58) and the ATCC 25923 strain. As shown in <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref> there was hardly any difference between the growth curves of the strains. All strains were able to grow in the presence of 5 mM D-Arg or 5 &#xb5;M CATH-2 separately, however when these compounds were both present growth of all strains was completely inhibited, except for strain JHs139, which started to grow after an 8&#xa0;h long lag phase (<xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2E</bold></xref>). Similar effects were seen in bacterial viability assays (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3</bold></xref>) where no viable bacteria were detected for all strains when 10 &#xb5;M CATH-2 and 5 mM D-Arg was present and very strong reductions in viable bacteria at a one-step lower concentration of 5 &#xb5;M CATH-2 and 5 mM D-Arg (the conditions similar to <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Effect of CATH-2 and D-Arg on growth of six S. aureus strains. S. aureus strains <bold>(A)</bold> S. aureus WKZ2, <bold>(B)</bold> S. aureus USA300, <bold>(C)</bold> S. aureus SauJes, <bold>(D)</bold> S. aureus JHs58, <bold>(E)</bold> S. aureus JHs139 and <bold>(F)</bold> S. aureus ATCC 25913 were grown with or without 5 &#xb5;M CATH-2 and/or 5 mM D-Arg at 37&#xa0;&#xb0;C. Growth was determined by measuring OD<sub>600</sub> every 10&#xa0;min. Growth curves are represented as mean &#xb1; SEM of three independent experiments. P-value, ***P &lt; 0.001, ****P &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g002.tif">
<alt-text content-type="machine-generated">Six-panel figure showing growth curves (OD600 over 24 hours) for bacterial strains WKZ2 (A), USA300 (B), SauJes (C), JHs58 (D), JHs139 (E), and ATCC 25923 (F), comparing LB alone, LB with D-Arg, LB with CATH-2, and LB with CATH-2 plus D-Arg. LB and LB plus D-Arg show highest growth, LB plus CATH-2 is reduced, and LB plus CATH-2 plus D-Arg shows nearly no growth. Statistically significant differences are indicated by asterisks.</alt-text>
</graphic></fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>CATH-2/D-Arg is active against multiple S. aureus strains. Colony count assays were performed on 6 S. aureus strain comparing the effect of CATH-2 alone and in combination with 5 mM D-Arg. <bold>(A)</bold> S. aureus USA300, <bold>(B)</bold> S. aureus ATCC 25913, <bold>(C)</bold> S. aureus SauJes <bold>(D)</bold> S. aureus JHs58, <bold>(E)</bold>&#xa0;S. aureus JHs139 and <bold>(F)</bold> <italic>S. aureus</italic> ATCC 25923. Bacteria were incubated with CATH-2 +/- 5 mM D-Arg for 3&#xa0;h at 37&#xa0;&#xb0;C Subsequently, bacterial viability was determined by plating out on TSA plates. Shown are the average + SEM of 3 independent experiments.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g003.tif">
<alt-text content-type="machine-generated">Six-panel scientific figure showing line graphs titled A) WKZ2, B) USA300, C) SauJes, D) JHs58, E) JHs139, and F) ATCC 25923, each illustrating bacterial counts (log CFU per milliliter) versus CATH-2 peptide concentration (micromolar), for two conditions: 0 millimolar D-Arg (blue lines) and 5 millimolar D-Arg (red lines); across all panels, increasing CATH-2 concentration leads to decreased bacterial levels, with the 5 millimolar D-Arg condition consistently showing lower bacterial counts.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_4">
<title>Antibacterial activity of the CATH-2/D-Arg combination against other mastitis causing bacteria</title>
<p>To investigate whether the CATH-2/D-Arg combination also had an effect on other mastitis causing bacteria like <italic>E. coli</italic>, <italic>S. uberis</italic> and <italic>S. agalactiae</italic>, we generated growth curves using varying concentrations of CATH-2 (0-5 &#xb5;M) and D-Arg (0 to 20 mM) (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;S3</bold></xref>-<xref ref-type="supplementary-material" rid="SM1"><bold>S5</bold></xref>). In contrast to <italic>S. aureus</italic>, increasing the concentration of CATH-2 alone strongly extended the lag phase of <italic>E. coli</italic> (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;S3</bold></xref>). The addition of D-Arg alone hardly affected the growth of <italic>E. coli</italic> and also in combination with 1.25 &#xb5;M CATH-2, addition of D-Arg resulted only in a minor additional effect on growth. At higher CATH-2 concentrations the peptide&#x2019;s effect alone was already (almost) completely blocking bacterial growth as no additional effects of D-Arg could be detected.</p>
<p>Both <italic>S. uberis</italic> and <italic>S. agalactiae</italic> were sensitive for D-Arg alone (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;S4A</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>S5A</bold></xref>), contrary to <italic>S. aureus</italic> and <italic>E. coli.</italic> While increasing D-Arg concentrations resulted in a similar lag-phase but clearly lower final optical density for <italic>S. uberis</italic>. For <italic>S. agalactiae</italic> the lag phase was strongly extended in the presence of D-Arg. Both strains were also very sensitive to CATH-2. In the presence of D-Arg and 2.5 &#xb5;M CATH-2 both strains were unable to grow (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figures&#xa0;4C</bold></xref>, <xref ref-type="supplementary-material" rid="SM1"><bold>S5C</bold></xref>), showing a higher sensitivity for these bacteria to CATH-2/D-Arg then <italic>S. aureus</italic>.</p>
</sec>
<sec id="s3_5">
<title>Detection of synergy between CATH-2 and D-Arg</title>
<p>To investigate whether CATH-2 and D-Arg exhibit a synergistic antibacterial effect against <italic>S. aureus</italic>, <italic>S. uberis</italic> and <italic>S. agalactiae</italic>, checkerboard assays in LB were performed (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4</bold></xref>). From this figure it is seen that the minimum inhibitory concentration of D-Arg is 40 mM for all three bacteria while CATH-2 prevented growth of <italic>S. aureus</italic>, <italic>S. uberis</italic> and <italic>S. agalactiae</italic> at 20, 20, and 5 &#xb5;M, respectively. Potential synergy was determined by calculating the fractional inhibitory concentration index (FICI), of the CATH-2/D-Arg combinations, FIC indices ranged from 0.375 &#x2013; 0.625 for specific ratios of CATH-2 and D-Arg. For example, the combination of 5 &#xb5;M CATH-2 and 5 mM D-Arg completely blocked <italic>S. aureus</italic> growth and resulted in a FIC index of 0.375, while other ratios such as 1.25 &#xb5;M CATH-2&#xa0;+&#xa0;20 mM D-Arg resulted in a FIC index just above 0.5. These results show that CATH-2 and D-Arg work synergistically against <italic>S. aureus</italic> and <italic>S. uberis</italic> but not against <italic>S. agalactiae</italic>.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Checkerboard assay shows synergistic combinations of CATH-2 and D-Arg. <italic>S. aureus JHs58</italic> <bold>(A)</bold><italic>, S. uberis</italic> 233 h4c1 <bold>(B)</bold> <italic>and S. agalactiae</italic> <bold>(C)</bold> were incubated with different ratios of CATH-2 (0-80 &#xb5;M) and D-Arg (0&#x2013;160 mM) in 96 wells plates. After 24&#xa0;h growth in each well was visually assessed and FIC indices were calculated for each combination where no growth was visible.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g004.tif">
<alt-text content-type="machine-generated">Figure contains three labeled panels (A, B, C), each showing a grid heatmap with D-Arginine concentrations on the vertical axis and CATH-2 concentrations on the horizontal axis. Green shaded cells indicate areas of growth, yellow cells no growth. Numeric values indicate FICI values below 0.5 means synergy.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_6">
<title>Synergistic activity of D-Arg and CATH-2 under an- vs aerobic conditions</title>
<p>Because mastitis leads to a dramatic drop in the oxygen concentration (<xref ref-type="bibr" rid="B16">Mayer et&#xa0;al., 1988</xref>) we investigated whether the CATH-2/D-Arg combination also works under anaerobic conditions. For this, <italic>S. aureus</italic> ATCC25923 and <italic>E. coli</italic> were incubated under anaerobic or aerobic conditions with 20 mM D-Arg, with or without 5 &#xb5;M CATH-2 (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5</bold></xref>). Under anaerobic as well as aerobic conditions, <italic>E. coli</italic> was highly sensitive to CATH-2 alone, and the combination of CATH-2 and D-Arg resulted in only a minor additional reduction of CFU (<xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5A, C</bold></xref>). In contrast to <italic>E. coli</italic>, CATH-2 alone had no effect on the growth of <italic>S. aureus</italic>, but the CATH-2/D-Arg combination killed all bacteria under both oxygen conditions (<xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5B, D</bold></xref>). In addition, the kinetics of killing <italic>S. aureus</italic> bacteria was similar for both oxygen conditions.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Antibacterial effect of CATH-2 and D-Arg under different oxygen conditions. E. coli <bold>(A, C)</bold> and S. aureus <bold>(B, D)</bold> were incubated under anaerobic <bold>(A, B)</bold> and aerobic <bold>(C, D)</bold> conditions with 5 &#xb5;M CATH-2 with or without 20 mM D-Arg for 3&#xa0;h. At the indicated time points samples were taken and 10-fold serial dilution were made and plated onto LB agar plates. After overnight incubation at 37&#xb0;C the CFigure were counted. Shown are the average + SEM of 3 independent experiments. P-value, *P &lt; 0.05, **P &lt; 0.01, ****P &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g005.tif">
<alt-text content-type="machine-generated">Panel A shows a line graph of log CFU per milliliter over 200 minutes, comparing four treatments: LB, LB plus D-Arg, LB plus CATH-2, and LB plus D-Arg plus CATH-2. Only the combination of D-Arg and CATH-2 results in a significant reduction in bacterial counts over time, while the other groups remain stable.  Panel B presents a similar line graph with lower initial CFU values. The LB plus D-Arg plus CATH-2 treatment immediately reduces CFU to the lowest level and maintains it, while other treatments show no substantial decline.  Panel C features a line graph where both CATH-2 alone and the LB plus D-Arg plus CATH-2 combination gradually reduce CFU counts, while LB and LB plus D-Arg remain steady over 200 minutes.  Panel D displays CFU counts where only the LB plus D-Arg plus CATH-2 group shows a rapid drop to the lowest values at the start, with other treatments resulting in stable CFU levels throughout the experiment.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_7">
<title>Toxicity assays LDH and WST towards Hela and Caco-2 cells</title>
<p>To investigate whether the CATH-2/D-Arg combination is toxic for eukaryotic cells, WST and LDH assays were performed on Hela and Caco-2 cells. Cells were incubated for 4&#xa0;h with different concentrations of CATH-2 and D-Arg. Above 10 &#xb5;M CATH-2 was toxic for the Hela cells (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6A, B</bold></xref>), but not for the Caco-2 cells (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6C, D</bold></xref>). Only the combination 40 &#xb5;M CATH-2 and 40 mM D-Arg, the highest concentration tested, was to some extend toxic for Caco-2 cells (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6D</bold></xref>). These results show that D-Arg is not toxic even at the highest concentration tested, but that CATH-2 shows some toxicity above 10 &#xb5;M for one cell line.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Effect of the CATH-2/D-Arg combination on the cell permeability, and metabolic activity of Hela and Caco cells. Permeability of the Hela cells were investigated by LDH <bold>(A)</bold> and metabolic activity by WST-1 <bold>(B)</bold> assays using different concentrations D-Arg and CATH-2. Permeability of the Caco cells were&#xa0;investigate by LDH <bold>(C)</bold> and metabolic activity by WST-1 <bold>(D)</bold> assays. Shown are the average + SEM of 4 independent experiments. P-value, **P &lt; 0.01, ***P &lt; 0.001, ****P &lt; 0.0001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g006.tif">
<alt-text content-type="machine-generated">Four grouped bar graphs labeled A, B, C, and D compare LDH and WST percentages for different treatments, including CATH-2, D-Arg, and controls. Significant differences are marked, with A and B showing strong statistical significance among some groups.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_8">
<title>Toxicity assay with PS (bMEC) cells</title>
<p>To obtain a more representative representation of the toxic effects of CATH-2 and D-Arg, the toxicity assay was additionally conducted on bovine mammary epithelial cells (PS cells). They were exposed to multiple concentrations of CATH-2 (0-40 &#xb5;M) and D-Arg (0&#x2013;40 mM) dissolved in raw cow milk, for a 1&#xa0;h and 4&#xa0;h duration (<xref ref-type="fig" rid="f7"><bold>Figures&#xa0;7A, B</bold></xref>, respectively). Because the presence of raw milk interfered with the LDH and WST assays, cell viability was assessed after exposure using a 1:1 ratio of Trypan Blue and RSM. The dead cells were counted and expressed as a percentage relative to the viable cells.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Effect of the CATH-2/D-Arg combination on bovine mammary epithelial (PS) cells in the presence of raw cow milk. PS cells suspended in raw cow milk were exposed to various concentrations CATH-2 (10-40 &#xb5;M) and D-Arg (10&#x2013;40 mM) for 1h <bold>(A)</bold> or 4h <bold>(B)</bold>. As a negative control, the cells were only exposed to a solution containing 85% raw milk and 15% water, and as a positive control, the cells were exposed to methanol. After incubation, the cells were stained with trypan blue. Dead cells were counted and expressed as a percentage to the total number of cells. Data are represented as mean + SEM of three independent experiments (n=3).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g007.tif">
<alt-text content-type="machine-generated">Bar graph with two panels, A and B, showing percentage of dead cells after 1 hour (A) and 4 hours (B) exposure to various treatments, including different concentrations of CATH-2, D-Arg, combinations, and controls. All treatments caused minimal cell death except methanol, which shows nearly 100 percent dead cells in both panels. Error bars and individual data points are indicated.</alt-text>
</graphic></fig>
<p>After 1 h of incubation, PS cells treated with CATH-2, D-Arg, or their combination exhibited a maximum toxicity of 2.35%, whereas the negative control (PS cells exposed only to raw cow milk) showed a similar toxicity of 1.25%. After 4 h, the maximum toxicity increased to 6.87%, while the negative control displayed 2.25% toxicity and the positive control (methanol) induced 100% toxicity. No morphological changes of the cells were observed for either incubation periods (data not shown). These results indicate that, under conditions most representative of the <italic>in vivo</italic> situation, the CATH-2/D-Arg combination is non&#x2212;toxic to bovine mammary epithelial cells.</p>
</sec>
<sec id="s3_9">
<title>Antibacterial activity of CATH-2 and D-Arg in raw milk</title>
<p>Since milk is the envisioned environment for treatment of mastitis, the antibacterial activity of CATH-2 in the presence or absence of D-Arg was tested in freshly obtained raw milk spiked with <italic>S. aureus</italic> ATCC25923. After treatment, milk was plated and after culture colony-forming units (CFU) were counted to measure bacterial survival. Interestingly, CATH-2 completely lost its antibacterial effect in milk (<xref ref-type="fig" rid="f8"><bold>Figures&#xa0;8A, B</bold></xref>, black lines) likely through activity-inhibiting components in the milk. Similarly, 40 mM D-Arg alone had no effect on the survival of the spiked <italic>S. aureus</italic> (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8A</bold></xref>). However, when both were combined a strong reduction in the number of viable bacteria was seen. At 5 &#xb5;M CATH-2 and 20 mM D-Arg more than 3-log reduction in CFU/ml was achieved within 3&#xa0;h, while 10 &#xb5;M CATH-2 and 20 mM D-Arg led to complete eradication of all bacteria after 1&#xa0;h (red lines <xref ref-type="fig" rid="f8"><bold>Figures&#xa0;8A, B</bold></xref>). Increasing the concentration of D-Arg further to 40 mM showed even faster kinetics of killing. Similar results were obtained when D-Lys was used instead of D-Arg, but D-Ser was unable to lower the <italic>S. aureus</italic> colony forming units (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;S6</bold></xref>). These results clearly indicate the potential of CATH-2 and D-Arg (or D-Lys) to kill <italic>S. aureus</italic> in raw milk.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Antibacterial activity of CATH-2 and D-Arg in raw milk. Raw milk was spiked with 1x10<sup>6</sup> CFU/ml S. aureus JHs58 and incubated with or without <bold>(A)</bold> 5&#xa0;&#xb5;M or <bold>(B)</bold> 10 &#xb5;M CATH-2 with 10, 20 or 40 mM D-Arg. At different time points small samples were taken and surviving bacteria enumerated by plating on TSA. Shown are the average + SEM of 3 independent experiments. P-value, **P &lt; 0.01, ***P &lt; 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g008.tif">
<alt-text content-type="machine-generated">Panel A shows a line graph with log CFU per milliliter on the y-axis and time in minutes on the x-axis, comparing the effects of S.A., D-Arg, and varying concentrations of CATH-2 and D-Arg. Panel B similarly displays a line graph, but with 10 micromolar CATH-2, showing greater bacterial reduction with increasing D-Arg concentration. Different symbols and colors represent treatment groups, and statistical significance is noted with asterisks in both panels.</alt-text>
</graphic></fig>
</sec>
<sec id="s3_10">
<title>Determination of synergy in raw milk.</title>
<p>To determine whether CATH-2 and D-Arg also exhibit a synergistic effect in raw milk, a checkerboard assay was performed. Since visual end-point registration is impossible in milk each well was plated out on TSA plates to detect viable bacteria. A representative example is shown in <xref ref-type="fig" rid="f9"><bold>Figure&#xa0;9</bold></xref> and shows that combinations starting from 10 &#xb5;M CATH-2 or 10 mM D-Arg resulted in complete killing of bacteria. With an MBC of 320 &#xb5;M for CATH-2 in milk and no detectable MBC for D-Arg (&gt;320 mM) (data not shown), FICI values were calculated to be between 0.1-0.3, all indicating strong synergy for these components in raw milk.</p>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>Checkerboard assay of antimicrobial activity of CATH-2 with D-Arg against S. aureus in raw milk. Raw milk was spiked with 1x10<sup>6</sup> CFU/ml S. aureus JHs58 and incubated with different ratios of CATH-2 (0-40 &#xb5;M) and D-Arg (0&#x2013;80 mM) in 96 wells plates. After 24&#xa0;h, survival of bacteria was assessed by plating out on TSA, and FIC indices were calculated for each combination where no viable bacteria were detected.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fcimb-16-1819326-g009.tif">
<alt-text content-type="machine-generated">Checkerboard assay in raw milk showing D-arginine on the y-as and CATH-2 concentrations on the x-as. Green means growth, yellow no growth. Numbers indicate FICI values.</alt-text>
</graphic></fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>The rapid emergence of antibiotic-resistant bacteria due to the overuse and misuse of these medications requires an urgent need for new drug development. AMPs have been shown to be active against a broad range of microorganisms, killing both Gram-positive and negative bacteria within a short time, while not inducing resistance (<xref ref-type="bibr" rid="B1">Ageitos et&#xa0;al., 2017</xref>; <xref ref-type="bibr" rid="B31">Veldhuizen et&#xa0;al., 2013</xref>). However, under physiological conditions they often lose their activity (<xref ref-type="bibr" rid="B22">Rima et&#xa0;al., 2021</xref>). Here we report that the positively charged D-amino acids D-Arginine and D-Lysine work synergistically with the antimicrobial peptide CATH-2 against the Gram-positive mastitis causing bacteria <italic>S. aureus</italic>, and <italic>S. uberis.</italic> Alone these compounds have hardly any antibacterial effect, however, combined they effectively kill these bacteria in raw cow milk.</p>
<p>As certain D-AAs are known to enhance the effectiveness of antibiotics (<xref ref-type="bibr" rid="B33">Yang et&#xa0;al., 2024</xref>), we sought to explore whether the addition of D-AAs could also boost the efficacy of the antimicrobial peptide CATH-2. All soluble D-amino acids at a concentration of 20 mM had no influence on the growth of <italic>S. aureus</italic> (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>), as also observed by other investigators (<xref ref-type="bibr" rid="B2">Alvarez et&#xa0;al., 2018</xref>). Also, no growth inhibition was observed when only 2 &#xb5;M CATH-2 was added confirming our previous results (<xref ref-type="bibr" rid="B31">Veldhuizen et&#xa0;al., 2013</xref>). For most D-amino acids, the combination with CATH-2 did not result in growth inhibition. However, a strong growth inhibition was seen when we combined the D-amino acids, D-Lysine or D-arginine with CATH-2. These combinations appear to work synergistically against the mastitis causing bacteria <italic>S. aureus</italic> and <italic>S. uberis</italic> and work well against <italic>S. agalactiae</italic> (<xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4</bold></xref>).</p>
<p>Mastitis is considered the costliest disease on dairy farms. Antibiotic treatment of mastitis cases is globally still the standard approach, both for acute cases during lactation using short acting formulations and chronic cases during the dry period using long acting formulations. Intramammary antibiotic therapy is generally recommended only for infections caused by Gram-positive bacteria such as <italic>S. aureus</italic> and <italic>S. agalactiae</italic> (<xref ref-type="bibr" rid="B11">Lago et&#xa0;al., 2011</xref>). In contrast, most Gram-negative infections are cleared by the cow&#x2019;s own immune system (<xref ref-type="bibr" rid="B20">Pyorala et&#xa0;al., 1994</xref>). However, in practice the causative agent is often not known and alle mastitis cases meeting specific criteria are treated. Alongside antibiotics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are widely used to reduce inflammation, pain, and fever associated with mastitis. NSAIDs can improve cure rates, but they are not antibacterial and therefore must be used in adjunction to antibiotics (<xref ref-type="bibr" rid="B18">Muzammil et&#xa0;al., 2022</xref>). Many mastitis-associated pathogens have become resistant to common antibiotics (<xref ref-type="bibr" rid="B15">Li et&#xa0;al., 2023</xref>; <xref ref-type="bibr" rid="B18">Muzammil et&#xa0;al., 2022</xref>). Bacteriophage therapy might be promising, however the CRISPR-Cas system which is widely distributed in bacteria can interfere by defending against specific types of phages (<xref ref-type="bibr" rid="B26">Shivram et&#xa0;al., 2021</xref>). Therefore, the combination of the AMP CATH-2 with the positively charged amino acids D-Arginine or D-lysine might be a hopeful combination to allow treatment of mastitis in the future.</p>
<p>Consistent with findings in mice (<xref ref-type="bibr" rid="B19">Navarro et&#xa0;al., 2005</xref>), D-Arg did not harm tissue culture cells (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6</bold></xref>, <xref ref-type="fig" rid="f7"><bold>7</bold></xref>). In contrast, CATH-2 caused some toxicity, however only at very high concentrations, while co-administration of CATH-2 and D-Arg significantly reduced this toxic effect (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6</bold></xref>). The data demonstrate that the interaction between D-arginine and CATH-2 actively mitigates toxicity rather than merely existing as a passive observation.</p>
<p>More importantly, no significant toxicity was observed with respect to udder cells exposed to milk alone or to milk containing the D-Arg/CATH-2 combination, even at the highest concentrations (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7</bold></xref>). These concentrations were far above the MIC in raw milk (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8</bold></xref>). Since this most closely resembles the <italic>in vivo</italic> situation, safety of potential intramammary application seems very well possible from a toxicity point of view.</p>
<p>The enhancing effect of D-Arginine and D-Lysine when combined with CATH-2 likely arises from synergistic mechanisms rather than direct binding. Indeed, we assessed binding between D-Arg and CATH-2 using isothermal titration calorimetry, but no detectable heat production indicative of binding could be detected (<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Figure&#xa0;S7</bold></xref>). D-Arg and D-Lys are the only two positively charged D-amino acids. The positive charge indicates that they can bind more easily to the negatively charged bacterial membrane (<xref ref-type="bibr" rid="B32">Wilson et&#xa0;al., 2001</xref>) then to the positively charged CATH-2. The compounds may facilitate entry into the bacterial cell for each other.</p>
<p>For most antimicrobial peptides, the mechanism of action involves bacterial membrane-permeabilization. The positively charged peptide electrostatically binds negatively charged membranes after which the peptides insert themselves in the membrane creating pores or destabilizing the membrane such that they become porous (<xref ref-type="bibr" rid="B17">Mookherjee et&#xa0;al., 2020</xref>). This mechanism applies also to CATH-2, although it has also been shown that this peptide can translocate into bacterial cells with minimal observable membrane damage at low concentrations. This enables CATH-2 to also access intracellular targets (<xref ref-type="bibr" rid="B25">Schneider et&#xa0;al., 2016</xref>). There is much less information on the antibacterial mechanism of D-amino acids, but tolerance to D-Arginine in bacteria has been associated with mutations in the phosphate transport and chaperone systems. This implies D-Arg targets cytoplasmic processes (<xref ref-type="bibr" rid="B2">Alvarez et&#xa0;al., 2018</xref>). The combination may allow D-Arg/D-Lys to exploit CATH-2-induced membrane perturbations to reach these intracellular sites without extracellular degradation. Synergistic effects could also stem from dual targeting: CATH-2 disrupts membrane integrity, while D-Arg/D-Lys interfere with metabolic pathways such as phosphate homeostasis or protein folding. This multi-pronged action might reduce the threshold for bacterial killing compared to either component alone.</p>
<p>It is unclear why the synergistic effect of CATH-2 and D-Arg in milk is even larger than in bacterial growth media. Milk is known to contain proteases, especially plasmin (derived from the inactive plasminogen), but in our opinion it is unlikely that the effect could be related to protease inactivation by the combination of CATH-2 and D-Arg. Plasmin is a trypsin like protease that cleaves peptide sequences indeed containing arginine or lysine but no reports of inhibition by free D-amino acids have been reported. An alternative explanation for synergy is that in milk the bacterial membrane might be covered or protected by milk components making it difficult for CATH-2 to penetrate the bacterial membrane, while the positively charged D-amino acid, due to electrostatic interactions with the negatively charged bacterial membrane can sensitize the membrane for CATH-2 penetration. However, this is all speculative and the exact mechanism of synergistic action is a subject for follow up studies.</p>
<p>The fast-killing kinetics and reduced quantities for killing bacteria observed for the CATH-2/D-Arg combination in raw milk reduces the hurdles of cost and instability of AMPs in physiological environments that have hampered much of the application of AMPs into useful drugs. It is anticipated that the production cost of the CATH-2/D-Arg formulation, intended for intramammary administration immediately post-milking in farm animals diagnosed with mastitis, will remain below &#x20ac;10 per treated animal, and if efficient large scale peptide production is achieved much lower than that.</p>
<p>Our research shows that a combination of natural compounds, positively charged D-amino acids and the antimicrobial peptide CATH-2, effectively eradicate mastitis-causing bacteria in raw cow milk. These novel synergistically working antibacterial compounds offer a promising potential for treating bacterial infections, particularly those caused by antibiotic-resistant strains and moves us nearer to combating the global threat of antibiotic resistance.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Material</bold></xref>. Further inquiries can be directed to the corresponding author.</p></sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. Ethical approval was not required for the studies on animals in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.</p></sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>EV: Investigation, Methodology, Supervision, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing. SV: Investigation, Methodology, Writing &#x2013; original draft. DA: Investigation, Writing &#x2013; original draft. LB: Methodology, Writing &#x2013; review &amp; editing. ID: Investigation, Writing &#x2013; original draft. IL: Investigation, Writing &#x2013; original draft. DS: Investigation, Writing &#x2013; original draft. MW: Conceptualization, Investigation, Methodology, Project administration, Supervision, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p></sec>
<ack>
<title>Acknowledgments</title>
<p>We thank Hodayse Miaei for her technical support. Henk Haagsman for carefully reading the manuscript and useful discussions.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s10" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcimb.2026.1819326/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcimb.2026.1819326/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="SupplementaryFile1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ageitos</surname> <given-names>J. M.</given-names></name>
<name><surname>Sanchez-Perez</surname> <given-names>A.</given-names></name>
<name><surname>Calo-Mata</surname> <given-names>P.</given-names></name>
<name><surname>Villa</surname> <given-names>T. G.</given-names></name>
</person-group> (<year>2017</year>). 
<article-title>Antimicrobial peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria</article-title>. <source>Biochem. Pharmacol.</source> <volume>133</volume>, <fpage>117</fpage>&#x2013;<lpage>138</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bcp.2016.09.018</pub-id>. PMID: <pub-id pub-id-type="pmid">27663838</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Alvarez</surname> <given-names>L.</given-names></name>
<name><surname>Aliashkevich</surname> <given-names>A.</given-names></name>
<name><surname>de Pedro</surname> <given-names>M. A.</given-names></name>
<name><surname>Cava</surname> <given-names>F.</given-names></name>
</person-group> (<year>2018</year>). 
<article-title>Bacterial secretion of D-arginine controls environmental microbial biodiversity</article-title>. <source>ISME J.</source> <volume>12</volume>, <fpage>438</fpage>&#x2013;<lpage>450</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ismej.2017.176</pub-id>. PMID: <pub-id pub-id-type="pmid">29028003</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bastings</surname> <given-names>J.</given-names></name>
<name><surname>van Eijk</surname> <given-names>H. M.</given-names></name>
<name><surname>Olde Damink</surname> <given-names>S. W.</given-names></name>
<name><surname>Rensen</surname> <given-names>S. S.</given-names></name>
</person-group> (<year>2019</year>). 
<article-title>D-amino acids in health and disease: a focus on cancer</article-title>. <source>Nutrients</source> <volume>11</volume>, <fpage>2205</fpage>.
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Diep</surname> <given-names>B. A.</given-names></name>
<name><surname>Gill</surname> <given-names>S. R.</given-names></name>
<name><surname>Chang</surname> <given-names>R. F.</given-names></name>
<name><surname>Phan</surname> <given-names>T. H.</given-names></name>
<name><surname>Chen</surname> <given-names>J. H.</given-names></name>
<name><surname>Davidson</surname> <given-names>M. G.</given-names></name>
<etal/>
</person-group>. (<year>2006</year>). 
<article-title>Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus</article-title>. <source>Lancet</source> <volume>367</volume>, <fpage>731</fpage>&#x2013;<lpage>739</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0140-6736(06)68231-7</pub-id>. PMID: <pub-id pub-id-type="pmid">16517273</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Goulart</surname> <given-names>D. B.</given-names></name>
<name><surname>Mellata</surname> <given-names>M.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Escherichia coli mastitis in dairy cattle: Etiology, diagnosis, and treatment challenges</article-title>. <source>Front. Microbiol.</source> <volume>13</volume>, <elocation-id>928346</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fmicb.2022.928346</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname> <given-names>C. S.</given-names></name>
<name><surname>Wong</surname> <given-names>C. T. H.</given-names></name>
<name><surname>Aung</surname> <given-names>T. T.</given-names></name>
<name><surname>Lakshminarayanan</surname> <given-names>R.</given-names></name>
<name><surname>Mehta</surname> <given-names>J. S.</given-names></name>
<name><surname>Rauz</surname> <given-names>S.</given-names></name>
<etal/>
</person-group>. (<year>2025</year>). 
<article-title>Antimicrobial resistance: a concise update</article-title>. <source>Lancet Microbe</source> <volume>6</volume>, <fpage>100947</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.lanmic.2024.07.010</pub-id>. PMID: <pub-id pub-id-type="pmid">39305919</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hoekstra</surname> <given-names>J.</given-names></name>
<name><surname>Rutten</surname> <given-names>V.</given-names></name>
<name><surname>Sommeling</surname> <given-names>L.</given-names></name>
<name><surname>van Werven</surname> <given-names>T.</given-names></name>
<name><surname>Spaninks</surname> <given-names>M.</given-names></name>
<name><surname>Duim</surname> <given-names>B.</given-names></name>
<etal/>
</person-group>. (<year>2018</year>). 
<article-title>High production of LukMF&#x2019; in field strains is associated with clinical bovine mastitis</article-title>. <source>Toxins</source> <volume>10</volume>, <page-range>200</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/toxins10050200</pub-id>. PMID: <pub-id pub-id-type="pmid">29762488</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Homma</surname> <given-names>H.</given-names></name>
</person-group> (<year>2007</year>). 
<article-title>Biochemistry of D-aspartate in mammalian cells</article-title>. <source>Amino Acids</source> <volume>32</volume>, <fpage>3</fpage>&#x2013;<lpage>11</lpage>.
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Inamullah</surname></name>
<name><surname>Kamal</surname> <given-names>M.</given-names></name>
<name><surname>Badshah</surname> <given-names>F.</given-names></name>
<name><surname>Khan</surname> <given-names>S.</given-names></name>
<name><surname>Tayh</surname> <given-names>G.</given-names></name>
<name><surname>Ben Said</surname> <given-names>M.</given-names></name>
<etal/>
</person-group>. (<year>2025</year>). 
<article-title>Prevalence and antimicrobial resistance characterization of multidrug-resistant Staphylococcus epidermidis isolated from raw milk of dairy cattle and ewes</article-title>. <source>PloS One</source> <volume>20</volume>, <elocation-id>e0334516</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0334516</pub-id>. PMID: <pub-id pub-id-type="pmid">41223199</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Jansen</surname> <given-names>W. T.</given-names></name>
<name><surname>Beitsma</surname> <given-names>M. M.</given-names></name>
<name><surname>Koeman</surname> <given-names>C. J.</given-names></name>
<name><surname>van Wamel</surname> <given-names>W. J.</given-names></name>
<name><surname>Verhoef</surname> <given-names>J.</given-names></name>
<name><surname>Fluit</surname> <given-names>A. C.</given-names></name>
</person-group> (<year>2006</year>). 
<article-title>Novel mobile variants of staphylococcal cassette chromosome mec in Staphylococcus aureus</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>50</volume>, <fpage>2072</fpage>&#x2013;<lpage>2078</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/aac.01539-05</pub-id>. PMID: <pub-id pub-id-type="pmid">16723568</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lago</surname> <given-names>A.</given-names></name>
<name><surname>Godden</surname> <given-names>S. M.</given-names></name>
<name><surname>Bey</surname> <given-names>R.</given-names></name>
<name><surname>Ruegg</surname> <given-names>P. L.</given-names></name>
<name><surname>Leslie</surname> <given-names>K.</given-names></name>
</person-group> (<year>2011</year>). 
<article-title>The selective treatment of clinical mastitis based on on-farm culture results: II. Effects on lactation performance, including clinical mastitis recurrence, somatic cell count, milk production, and cow survival</article-title>. <source>J. Dairy Sci.</source> <volume>94</volume>, <fpage>4457</fpage>&#x2013;<lpage>4467</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3168/jds.2010-4047</pub-id>. PMID: <pub-id pub-id-type="pmid">21854918</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lam</surname> <given-names>H.</given-names></name>
<name><surname>Oh</surname> <given-names>D. C.</given-names></name>
<name><surname>Cava</surname> <given-names>F.</given-names></name>
<name><surname>Takacs</surname> <given-names>C. N.</given-names></name>
<name><surname>Clardy</surname> <given-names>J.</given-names></name>
<name><surname>de Pedro</surname> <given-names>M. A.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). 
<article-title>D-amino acids govern stationary phase cell wall remodeling in bacteria</article-title>. <source>Science</source> <volume>325</volume>, <fpage>1552</fpage>&#x2013;<lpage>5</lpage>.
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Leiman</surname> <given-names>S. A.</given-names></name>
<name><surname>May</surname> <given-names>J. M.</given-names></name>
<name><surname>Lebar</surname> <given-names>M. D.</given-names></name>
<name><surname>Kahne</surname> <given-names>D.</given-names></name>
<name><surname>Kolter</surname> <given-names>R.</given-names></name>
<name><surname>Losick</surname> <given-names>R.</given-names></name>
</person-group> (<year>2013</year>). 
<article-title>D-amino acids indirectly inhibit biofilm formation in Bacillus subtilis by interfering with protein synthesis</article-title>. <source>J. Bacteriol.</source> <volume>195</volume>, <fpage>5391</fpage>&#x2013;<lpage>5395</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/jb.00975-13</pub-id>. PMID: <pub-id pub-id-type="pmid">24097941</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>H.</given-names></name>
<name><surname>Anuwongcharoen</surname> <given-names>N.</given-names></name>
<name><surname>Malik</surname> <given-names>A. A.</given-names></name>
<name><surname>Prachayasittikul</surname> <given-names>V.</given-names></name>
<name><surname>Wikberg</surname> <given-names>J. E.</given-names></name>
<name><surname>Nantasenamat</surname> <given-names>C.</given-names></name>
</person-group> (<year>2016</year>). 
<article-title>Roles of d-Amino Acids on the Bioactivity of Host Defense Peptides</article-title>. <source>Int. J. Mol. Sci.</source> <volume>17</volume>, <page-range>1023</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms17071023</pub-id>. PMID: <pub-id pub-id-type="pmid">27376281</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname> <given-names>X.</given-names></name>
<name><surname>Xu</surname> <given-names>C.</given-names></name>
<name><surname>Liang</surname> <given-names>B.</given-names></name>
<name><surname>Kastelic</surname> <given-names>J. P.</given-names></name>
<name><surname>Han</surname> <given-names>B.</given-names></name>
<name><surname>Tong</surname> <given-names>X.</given-names></name>
<etal/>
</person-group>. (<year>2023</year>). 
<article-title>Alternatives to antibiotics for treatment of mastitis in dairy cows</article-title>. <source>Front. Vet. Sci.</source> <volume>10</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fvets.2023.1160350</pub-id>. PMID: <pub-id pub-id-type="pmid">37404775</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mayer</surname> <given-names>S. J.</given-names></name>
<name><surname>Waterman</surname> <given-names>A. E.</given-names></name>
<name><surname>Keen</surname> <given-names>P. M.</given-names></name>
<name><surname>Craven</surname> <given-names>N.</given-names></name>
<name><surname>Bourne</surname> <given-names>F. J.</given-names></name>
</person-group> (<year>1988</year>). 
<article-title>Oxygen concentration in milk of healthy and mastitic cows and implications of low oxygen tension for the killing of Staphylococcus aureus by bovine neutrophils</article-title>. <source>J. Dairy Res.</source> <volume>55</volume>, <fpage>513</fpage>&#x2013;<lpage>519</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1017/s0022029900033288</pub-id>. PMID: <pub-id pub-id-type="pmid">3235718</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mookherjee</surname> <given-names>N.</given-names></name>
<name><surname>Anderson</surname> <given-names>M. A.</given-names></name>
<name><surname>Haagsman</surname> <given-names>H. P.</given-names></name>
<name><surname>Davidson</surname> <given-names>D. J.</given-names></name>
</person-group> (<year>2020</year>). 
<article-title>Antimicrobial host defence peptides: functions and clinical potential</article-title>. <source>Nat. Rev. Drug Discov.</source> <volume>19</volume>, <fpage>311</fpage>&#x2013;<lpage>332</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41573-019-0058-8</pub-id>. PMID: <pub-id pub-id-type="pmid">32107480</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Muzammil</surname> <given-names>I.</given-names></name>
<name><surname>Ijaz</surname> <given-names>M.</given-names></name>
<name><surname>Saleem</surname> <given-names>M. H.</given-names></name>
<name><surname>Ali</surname> <given-names>M. M.</given-names></name>
</person-group> (<year>2022</year>). 
<article-title>Drug repurposing strategy: An emerging approach to identify potential therapeutics for treatment of bovine mastitis</article-title>. <source>Microb. Pathog.</source> <volume>171</volume>, <elocation-id>105691</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.micpath.2022.105691</pub-id>. PMID: <pub-id pub-id-type="pmid">35995254</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Navarro</surname> <given-names>E.</given-names></name>
<name><surname>Alonso</surname> <given-names>S. J.</given-names></name>
<name><surname>Martin</surname> <given-names>F. A.</given-names></name>
<name><surname>Castellano</surname> <given-names>M. A.</given-names></name>
</person-group> (<year>2005</year>). 
<article-title>Toxicological and pharmacological effects of D-arginine</article-title>. <source>Basic Clin. Pharmacol. Toxicol.</source> <volume>97</volume>, <fpage>149</fpage>&#x2013;<lpage>154</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1742-7843.2005.pto_973110.x</pub-id>. PMID: <pub-id pub-id-type="pmid">16128908</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pyorala</surname> <given-names>S.</given-names></name>
<name><surname>Kaartinen</surname> <given-names>L.</given-names></name>
<name><surname>Kack</surname> <given-names>H.</given-names></name>
<name><surname>Rainio</surname> <given-names>V.</given-names></name>
</person-group> (<year>1994</year>). 
<article-title>Efficacy of two therapy regimens for treatment of experimentally induced Escherichia coli mastitis in cows</article-title>. <source>J.&#xa0;Dairy Sci.</source> <volume>77</volume>, <fpage>453</fpage>&#x2013;<lpage>461</lpage>.
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rainard</surname> <given-names>P.</given-names></name>
<name><surname>Foucras</surname> <given-names>G.</given-names></name>
<name><surname>Fitzgerald</surname> <given-names>J. R.</given-names></name>
<name><surname>Watts</surname> <given-names>J. L.</given-names></name>
<name><surname>Koop</surname> <given-names>G.</given-names></name>
<name><surname>Middleton</surname> <given-names>J. R.</given-names></name>
</person-group> (<year>2018</year>). 
<article-title>Knowledge gaps and research priorities in Staphylococcus aureus mastitis control</article-title>. <source>Transbound Emerg. Dis.</source> <volume>65</volume>, <fpage>149</fpage>&#x2013;<lpage>165</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/tbed.12698</pub-id>. PMID: <pub-id pub-id-type="pmid">28984427</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rima</surname> <given-names>M.</given-names></name>
<name><surname>Rima</surname> <given-names>M.</given-names></name>
<name><surname>Fajloun</surname> <given-names>Z.</given-names></name>
<name><surname>Sabatier</surname> <given-names>J. M.</given-names></name>
<name><surname>Bechinger</surname> <given-names>B.</given-names></name>
<name><surname>Naas</surname> <given-names>T.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Antimicrobial peptides: A potent alternative to antibiotics</article-title>. <source>Antibiotics (Basel)</source> <volume>10</volume>, <page-range>1095</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/antibiotics10091095</pub-id>. PMID: <pub-id pub-id-type="pmid">34572678</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rodriguez</surname> <given-names>M. S.</given-names></name>
<name><surname>Thompson</surname> <given-names>J.</given-names></name>
<name><surname>Hay</surname> <given-names>R. T.</given-names></name>
<name><surname>Dargemont</surname> <given-names>C.</given-names></name>
</person-group> (<year>1999</year>). 
<article-title>Nuclear retention of IkappaBalpha protects it from signal-induced degradation and inhibits nuclear factor kappaB transcriptional activation</article-title>. <source>J. Biol. Chem.</source> <volume>274</volume>, <fpage>9108</fpage>&#x2013;<lpage>9115</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.274.13.9108</pub-id>. PMID: <pub-id pub-id-type="pmid">10085161</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Roussel</surname> <given-names>P.</given-names></name>
<name><surname>Cunha</surname> <given-names>P.</given-names></name>
<name><surname>Porcherie</surname> <given-names>A.</given-names></name>
<name><surname>Petzl</surname> <given-names>W.</given-names></name>
<name><surname>Gilbert</surname> <given-names>F. B.</given-names></name>
<name><surname>Riollet</surname> <given-names>C.</given-names></name>
<etal/>
</person-group>. (<year>2015</year>). 
<article-title>Investigating the contribution of IL-17A and IL-17F to the host response during Escherichia coli mastitis</article-title>. <source>Vet. Res.</source> <volume>46</volume>, <elocation-id>56</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13567-015-0201-4</pub-id>. PMID: <pub-id pub-id-type="pmid">26062913</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Schneider</surname> <given-names>V. A.</given-names></name>
<name><surname>Coorens</surname> <given-names>M.</given-names></name>
<name><surname>Ordonez</surname> <given-names>S. R.</given-names></name>
<name><surname>Tjeerdsma-van Bokhoven</surname> <given-names>J. L.</given-names></name>
<name><surname>Posthuma</surname> <given-names>G.</given-names></name>
<name><surname>van Dijk</surname> <given-names>A.</given-names></name>
<etal/>
</person-group>. (<year>2016</year>). 
<article-title>Imaging the antimicrobial mechanism(s) of cathelicidin-2</article-title>. <source>Sci. Rep.</source> <volume>6</volume>, <elocation-id>32948</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep32948</pub-id>. PMID: <pub-id pub-id-type="pmid">27624595</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Shivram</surname> <given-names>H.</given-names></name>
<name><surname>Cress</surname> <given-names>B. F.</given-names></name>
<name><surname>Knott</surname> <given-names>G. J.</given-names></name>
<name><surname>Doudna</surname> <given-names>J. A.</given-names></name>
</person-group> (<year>2021</year>). 
<article-title>Controlling and enhancing CRISPR systems</article-title>. <source>Nat. Chem. Biol.</source> <volume>17</volume>, <fpage>10</fpage>&#x2013;<lpage>19</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41589-020-00700-7</pub-id>. PMID: <pub-id pub-id-type="pmid">33328654</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Swanson</surname> <given-names>K. M.</given-names></name>
<name><surname>Stelwagen</surname> <given-names>K.</given-names></name>
<name><surname>Dobson</surname> <given-names>J.</given-names></name>
<name><surname>Henderson</surname> <given-names>H. V.</given-names></name>
<name><surname>Davis</surname> <given-names>S. R.</given-names></name>
<name><surname>Farr</surname> <given-names>V. C.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). 
<article-title>Transcriptome profiling of Streptococcus uberis-induced mastitis reveals fundamental differences between immune gene expression in the mammary gland and in a primary cell culture model</article-title>. <source>J. Dairy Sci.</source> <volume>92</volume>, <fpage>117</fpage>&#x2013;<lpage>129</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3168/jds.2008-1382</pub-id>. PMID: <pub-id pub-id-type="pmid">19109270</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Urakawa</surname> <given-names>M.</given-names></name>
<name><surname>Zhuang</surname> <given-names>T.</given-names></name>
<name><surname>Sato</surname> <given-names>H.</given-names></name>
<name><surname>Takanashi</surname> <given-names>S.</given-names></name>
<name><surname>Yoshimura</surname> <given-names>K.</given-names></name>
<name><surname>Endo</surname> <given-names>Y.</given-names></name>
<etal/>
</person-group>. (<year>2022</year>). 
<article-title>Prevention of mastitis in multiparous dairy cows with a previous history of mastitis by oral feeding with probiotic Bacillus subtilis</article-title>. <source>Anim Sci. J.</source> <volume>93</volume>, <elocation-id>e13764</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/asj.13764</pub-id>. PMID: <pub-id pub-id-type="pmid">36085592</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>van Dijk</surname> <given-names>A.</given-names></name>
<name><surname>Molhoek</surname> <given-names>E. M.</given-names></name>
<name><surname>Veldhuizen</surname> <given-names>E. J.</given-names></name>
<name><surname>Bokhoven</surname> <given-names>J. L.</given-names></name>
<name><surname>Wagendorp</surname> <given-names>E.</given-names></name>
<name><surname>Bikker</surname> <given-names>F.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). 
<article-title>Identification of chicken cathelicidin-2 core elements involved in antibacterial and immunomodulatory activities</article-title>. <source>Mol. Immunol.</source> <volume>46</volume>, <fpage>2465</fpage>&#x2013;<lpage>2473</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2009.05.019</pub-id>. PMID: <pub-id pub-id-type="pmid">19524300</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>van Soest</surname> <given-names>F. J. S.</given-names></name>
<name><surname>Santman-Berends</surname> <given-names>I.</given-names></name>
<name><surname>Lam</surname> <given-names>T.</given-names></name>
<name><surname>Hogeveen</surname> <given-names>H.</given-names></name>
</person-group> (<year>2016</year>). 
<article-title>Failure and preventive costs of mastitis on Dutch dairy farms</article-title>. <source>J. Dairy Sci.</source> <volume>99</volume>, <fpage>8365</fpage>&#x2013;<lpage>8374</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3168/jds.2015-10561</pub-id>. PMID: <pub-id pub-id-type="pmid">27474980</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Veldhuizen</surname> <given-names>E. J.</given-names></name>
<name><surname>Brouwer</surname> <given-names>E. C.</given-names></name>
<name><surname>Schneider</surname> <given-names>V. A.</given-names></name>
<name><surname>Fluit</surname> <given-names>A. C.</given-names></name>
</person-group> (<year>2013</year>). 
<article-title>Chicken cathelicidins display antimicrobial activity against multiresistant bacteria without inducing strong resistance</article-title>. <source>PloS One</source> <volume>8</volume>, <elocation-id>e61964</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0061964</pub-id>. PMID: <pub-id pub-id-type="pmid">23613986</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wilson</surname> <given-names>W. W.</given-names></name>
<name><surname>Wade</surname> <given-names>M. M.</given-names></name>
<name><surname>Holman</surname> <given-names>S. C.</given-names></name>
<name><surname>Champlin</surname> <given-names>F. R.</given-names></name>
</person-group> (<year>2001</year>). 
<article-title>Figure Status of methods for assessing bacterial cell surface charge properties based on zeta potential measurements</article-title>. <source>J. Microbiol. Methods</source> <volume>43</volume>, <fpage>153</fpage>&#x2013;<lpage>164</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0167-7012(00)00224-4</pub-id>. PMID: <pub-id pub-id-type="pmid">11118650</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname> <given-names>J.</given-names></name>
<name><surname>Ran</surname> <given-names>Y.</given-names></name>
<name><surname>Liu</surname> <given-names>S.</given-names></name>
<name><surname>Ren</surname> <given-names>C.</given-names></name>
<name><surname>Lou</surname> <given-names>Y.</given-names></name>
<name><surname>Ju</surname> <given-names>P.</given-names></name>
<etal/>
</person-group>. (<year>2024</year>). 
<article-title>Synergistic D-Amino Acids Based Antimicrobial Cocktails Formulated via High-Throughput Screening and Machine Learning</article-title>. <source>Adv. Sci. (Weinh)</source> <volume>11</volume>, <elocation-id>e2307173</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/advs.202307173</pub-id>. PMID: <pub-id pub-id-type="pmid">38126652</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/374555">Joel E. Lopez-Meza</ext-link>, Michoacana University of San Nicol&#xe1;s de Hidalgo, Mexico</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2695329">Andrea Bosso</ext-link>, University of Naples Federico II, Italy</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2195017">Salma Al Adwani</ext-link>, Sultan Qaboos University, Oman</p></fn>
</fn-group>
</back>
</article>